Author:
Katragkou Aspasia,McCarthy Matthew,Meletiadis Joseph,Petraitis Vidmantas,Moradi Patriss W.,Strauss Gittel E.,Fouant Monique M.,Kovanda Laura L.,Petraitiene Ruta,Roilides Emmanuel,Walsh Thomas J.
Abstract
ABSTRACTWhether isavuconazole, an extended-spectrum triazole, possesses synergistic activity in combination therapy with echinocandins or amphotericin B for the treatment of invasive molds infections has not been studied. Ourin vitrocombination studies showed that isavuconazole and micafungin are synergistically active againstAspergillus fumigatus,Aspergillus flavus,Aspergillus terreus, andCunninghamella bertholletiae. These results suggest that isavuconazole, in combination with micafungin, may have a role in the treatment of invasive aspergillosis and warrants further investigation.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference23 articles.
1. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study;Pagano;Haematologica,2006
2. Population-based survey of filamentous fungi and antifungal resistance in Spain (FILPOP study);Alastruey-Izquierdo;Antimicrob. Agents Chemother.,2013
3. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment;Pfaller;Am. J. Med.,2012
4. Pulmonary aspergillosis: recent advances;Thompson;Semin. Respir. Crit. Care Med.,2011
5. How does antifungal pharmacology differ for mucormycosis versus aspergillosis?;Lewis;Clin. Infect. Dis.,2012
Cited by
38 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献